Endobronchial ultrasound biopsy (EBUS) is a minimally invasive procedure that helps visualize structures in and around the lungs. EBUS uses an ultrasound device to guide a bronchoscope through the mouth and into the lungs. This allows real-time imaging and biopsy of lymph nodes and lung tumors as small as 5-10 mm.
The global Endobronchial Ultrasound Biopsy Market is estimated to be valued at US$ 722.67 billion in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing incidences of lung cancer is a major factor fueling the growth of this market. It is estimated that over 2.1 million new cases of lung cancer were diagnosed in 2018 according to GLOBOCAN. Additionally, lung cancer remains the leading cause of cancer death worldwide, accounting for around 1.8 million lung cancer deaths in 2018. Early diagnosis of lung cancer is crucial for effective treatment and improved patient outcomes. EBUS helps detect cancer in its early stages by allowing visualization and biopsy of even small lung tumors. This is expected to drive greater adoption of EBUS procedures for diagnosis of lung cancer over the forecast period.
Segment Analysis
The global endobronchial ultrasound biopsy market is dominated by the tru-cut biopsy segment, which holds a market share of over 40%. This is because tru-cut biopsy provides core biopsy samples and allows diagnosis of malignant and benign lesions. It can also be used to biopsy lymph nodes and masses adjacent to the airways or lung parenchyma under real-time ultrasound guidance through the bronchoscope.
Key Takeaways
The global Endobronchial Ultrasound Biopsy Market Share is expected to witness high growth.
Regional analysis: The Asia Pacific region is expected to witness the highest growth in the endobronchial ultrasound biopsy market during the forecast period. This is attributed to increasing healthcare expenditure, growing cancer incidence, rising awareness about ultrasound biopsy procedures, and developing healthcare infrastructure in emerging APAC countries.
Key players operating in the endobronchial ultrasound biopsy market are Alf Engineering, F-TECH, Magna International, Metalsa, Nissin Kogyo, Sango Co., Ltd., Tata Precision Tubes, Tenneco, Thyssenkrupp AG, Vari-Form, and Yorozu.
Get More Insights On This Topic: https://www.newsanalyticspro.com/the-endobronchial-ultrasound-biopsy-market-driven-by-rising-need/
Endobronchial valves were developed primarily by the start-up medical device company Emphasys Medical (now Pulmonx - Redwood City, California) as a minimally invasive alternative to lung volume reduction surgery for emphysema.
In lung volume reduction surgery, a surgeon cuts into a patient's chest and cuts out one or more diseased portion(s) of a lung.
Endobronchial valves were designed to replicate the effects of that procedure without requiring incisions, by simply allowing the most diseased portions of the lung to collapse.
Emphasys was purchased by Pulmonx in 2009Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for The global endobronchial valves market which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery.
Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US.The major factor expected to drive the growth of the endobronchial valves market is growing awareness regarding procedure for bronchoscopic lung volume reduction in various lung-related diseases.
The increasing prevalence of tobacco smoking worldwide is consequently expected to contribute to the growth of the endobronchial valves market.
